A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer

Murine Monoclonal Antibody ◽

Phase 2 ◽

Pilot Phase ◽

Immunotherapeutic Agent ◽

An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-3546 ◽

2021 ◽

pp. clincanres.3546.2020

Author(s):

Ning Li ◽

Hualei Bu ◽

Jihong Liu ◽

Jianqing Zhu ◽

Qi Zhou ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase 2 ◽

Open Label ◽

Platinum Sensitive ◽

Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.02.009 ◽

2015 ◽

Vol 137 (2) ◽

pp. 223-228 ◽

Cited By ~ 74

Author(s):

Clemens B. Tempfer ◽

Guido Winnekendonk ◽

Wiebke Solass ◽

Reinhard Horvat ◽

Urs Giger-Pabst ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase 2 ◽

Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer

American Journal of Obstetrics and Gynecology ◽

10.1067/mob.2003.347 ◽

2003 ◽

Vol 189 (1) ◽

pp. 28-36 ◽

Cited By ~ 44

Author(s):

Volker J. Möbus ◽

Richard P. Baum ◽

Marcus Bolle ◽

Rolf Kreienberg ◽

Antoine A. Noujaim ◽

...

Keyword(s):

Ovarian Cancer ◽

Monoclonal Antibody ◽

Immune Responses ◽

Murine Monoclonal Antibody ◽

Prolonged Survival

Randomized Phase 2 Study of Investigational, Selective Aurora a Kinase Inhibitor Alisertib (Mln8237) with Weekly Paclitaxel Vs Paclitaxel Alone in Patients (Pts) with Recurrent Ovarian Cancer (Oc)

Annals of Oncology ◽

10.1093/annonc/mdu338.2 ◽

2014 ◽

Vol 25 ◽

pp. iv305 ◽

Cited By ~ 3

Author(s):

R. Coleman ◽

A. Roszak ◽

K. Behbakht ◽

I.L. Ray-Coquard ◽

U. Matulonis ◽

...

Keyword(s):

Ovarian Cancer ◽

Kinase Inhibitor ◽

Weekly Paclitaxel ◽

Aurora A Kinase ◽

Phase 2 ◽

Aurora A ◽

Phase 2 Study ◽

Randomized Phase 2

PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression

Journal of Gynecologic Oncology ◽

10.3802/jgo.2019.30.e86 ◽

2019 ◽

Vol 30 (5) ◽

Cited By ~ 3

Author(s):

Peey-Sei Kok ◽

Philip Beale ◽

Rachel L. O'Connell ◽

Peter Grant ◽

Tony Bonaventura ◽

...

Keyword(s):

Ovarian Cancer ◽

Progesterone Receptor ◽

Estrogen And Progesterone Receptor

Phase 2 ◽

Asymptomatic Patients ◽

Phase 2 Study ◽

Positive Recurrent ◽

8000 Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: preliminary data from a phase-2 study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71522-8 ◽

2009 ◽

Vol 7 (2) ◽

pp. 450 ◽

Cited By ~ 3

Author(s):

D.K. Armstrong ◽

R. Coleman ◽

A.J. White ◽

A. Bicher ◽

D.G. Gibbon ◽

...

Keyword(s):

Ovarian Cancer ◽

Monoclonal Antibody ◽

Preliminary Data ◽

Folate Receptor ◽

Phase 2 ◽

Efficacy And Safety ◽

Receptor Alpha ◽

Platinum Sensitive ◽

Humanized Monoclonal Antibody ◽

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(14)70391-2 ◽

2014 ◽

Vol 15 (11) ◽

pp. 1207-1214 ◽

Cited By ~ 328

Author(s):

Joyce F Liu ◽

William T Barry ◽

Michael Birrer ◽

Jung-Min Lee ◽

Ronald J Buckanovich ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase 2 ◽

Platinum Sensitive ◽

Are Daily Orthogonal kVkV Images Sufficient for Image Guided Radiation Therapy of Prostate Cancer Patients Post-Radical Prostatectomy? Final Analysis of a Pilot Phase 2 Study

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2013.06.969 ◽

2013 ◽

Vol 87 (2) ◽

pp. S369

Author(s):

T.M. Niazi ◽

J. Papayanatos ◽

N. Tomic ◽

B. Bahoric ◽

F. Bladou ◽

...

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

Radical Prostatectomy ◽

Cancer Patients ◽

Final Analysis ◽

Phase 2 ◽

Pilot Phase ◽

Image Guided Radiation Therapy ◽

Image Guided ◽

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Investigational New Drugs ◽

10.1007/s10637-012-9869-8 ◽

2012 ◽

Vol 31 (3) ◽

pp. 760-768 ◽

Cited By ~ 143

Author(s):

Kenneth J. Pienta ◽

Jean-Pascal Machiels ◽

Dirk Schrijvers ◽

Boris Alekseev ◽

Mikhail Shkolnik ◽

...

Keyword(s):

Prostate Cancer ◽

Monoclonal Antibody ◽

Human Monoclonal Antibody ◽

Phase 2 ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Phase 2 Study ◽

Chemokine Ligand ◽

Cc Chemokine Ligand 2 ◽

Chemokine Ligand 2

PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miUBC)

Annals of Oncology ◽

10.1093/annonc/mdw373.74 ◽

2016 ◽

Vol 27 ◽

pp. vi294

Author(s):

A. Necchi ◽

L. Mariani ◽

A. Anichini ◽

P. Giannatempo ◽

D. Raggi ◽

...

Keyword(s):

Monoclonal Antibody ◽

Neoadjuvant Therapy ◽

Bladder Carcinoma ◽

Phase 2 ◽

Open Label ◽

Urothelial Bladder Carcinoma ◽

Programmed Death ◽

Phase 2 Study ◽

Urothelial Bladder ◽

Muscle Invasive